AnaptysBio GAAP EPS of $0.11 misses by $0.28, revenue of $30.27M misses by $3.19M

AnaptysBio reported Q1 GAAP EPS of $0.11, missing estimates by $0.28, and revenue of $30.27M, missing by $3.19M. Revenue fell 60.3% year-over-year, according to the company.

Original reporting
Published Nov 12, 2026, 9:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ANAB
Bearish
high confidence
Mentioned
$ANAB
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ANABBearishMed
01

Why it matters

The earnings shortfall is likely to trigger short‑term selling pressure, though longer‑term valuation will depend on pipeline milestones.

02

Market read

Micro‑cap biotech earnings miss, relevant for short‑term traders and biotech sector watchers.

03

What to watch

Potential upcoming clinical trial data or partnership announcements could offset the earnings disappointment.

Relevance 6/10Novelty 7/10Timing: after-hours release

Background

AnaptysBio released its Q1 2026 GAAP earnings, reporting a significant miss on both EPS and revenue.

Company-level read

Ticker impact

$ANABBearishHigh confidence
Context

Q1 GAAP EPS of $0.11 missed expectations by $0.28 and revenue of $30.27M missed by $3.19M, marking the first public disclosure of the quarter's results.

Expected impact

downward pressure as investors price in the earnings shortfall

Evidence & confidence

Both EPS and revenue fell short of expectations, a clear negative catalyst for a micro‑cap biotech.

Market effects

Biotech sector may see modest pullback as earnings miss adds to sector risk sentiment.

US biotech stocks could see slight weakness in late‑day trading.

Limited to investors tracking small‑cap biotech earnings.

Counterpoint

If the miss is viewed as a temporary setback and pipeline progress remains strong, the stock could be a buying opportunity at lower levels.

Key entities

  • AnaptysBio, Inc.

    US‑listed biotech company (NASDAQ: ANAB) reporting Q1 results.

Related articles

$ANABHighAI 8/10

ANAPTYSBIO, INC (ANAB): Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update • Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth • Jemperli approved in the U.S. as

$ANABHighAI 9/10

AnaptysBio, Inc. (ANAB) Gets FDA OK for Jemperli in MSI-H/dMMR Rectal Cancer

AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli as the first immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer. The approval, based on AZUR-1 data, shows 68% of participants had no detectable cancer after one year, with no recurrences reported after 2+ years of follow-up. GSK will present full data at ESMO Congress 2026.

$ANABHighAI 9/10

AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo

AnaptysBio (ANAB) shares rose after partner GSK received FDA approval for an expanded label of anti-PD-1 therapy Jemperli. The approval allows marketing for a new cancer indication, accelerating regulatory action. ANAB's P/E ratio is 7.64x, below its 5-year median. Insider activity shows net selling. ANAB's GF Score is 43/100, reflecting mixed fundamentals.

$ANABHighAI 8/10

AnaptysBio gains as GSK granted FDA label expansion for Jemperli

AnaptysBio (ANAB) rose after partner GSK (GSK) received FDA approval to expand Jemperli's label for treating certain rectal cancers. The drug is now approved for adults with stage II/III MSI-H/dMMR locally advanced rectal cancer, a subset of 5%-10% of rectal cancers. The approval came earlier than the expected February 2027 date.